These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37037265)

  • 1. Sirtuin1-p53: A potential axis for cancer therapy.
    Yin JY; Lu XT; Hou ML; Cao T; Tian Z
    Biochem Pharmacol; 2023 Jun; 212():115543. PubMed ID: 37037265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming.
    Ong ALC; Ramasamy TS
    Ageing Res Rev; 2018 May; 43():64-80. PubMed ID: 29476819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT1 and p53, effect on cancer, senescence and beyond.
    Yi J; Luo J
    Biochim Biophys Acta; 2010 Aug; 1804(8):1684-9. PubMed ID: 20471503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation.
    Jia X; Liu H; Ren X; Li P; Song R; Li X; Guo Y; Li X
    Oncogene; 2022 Sep; 41(39):4474-4484. PubMed ID: 36030331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous NAD(+) supplementation protects H9c2 cardiac myoblasts against hypoxia/reoxygenation injury via Sirt1-p53 pathway.
    Liu L; Wang P; Liu X; He D; Liang C; Yu Y
    Fundam Clin Pharmacol; 2014 Apr; 28(2):180-9. PubMed ID: 23384296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSAG2 is a cancer-specific activator of SIRT1.
    Yang X; Potts PR
    EMBO Rep; 2020 Sep; 21(9):e50912. PubMed ID: 32761762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum withdrawal up-regulates human SIRT1 gene expression in a p53-dependent manner.
    Shang L; Zhou H; Xia Y; Wang H; Gao G; Chen B; Liu Q; Shao C; Gong Y
    J Cell Mol Med; 2009 Oct; 13(10):4176-84. PubMed ID: 19267881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells.
    Zhao H; Tang W; Chen X; Wang S; Wang X; Xu H; Li L
    Biochem Biophys Res Commun; 2017 Nov; 493(1):77-84. PubMed ID: 28919418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.
    Magni M; Buscemi G; Maita L; Peng L; Chan SY; Montecucco A; Delia D; Zannini L
    Cell Death Differ; 2019 May; 26(5):918-931. PubMed ID: 30050056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
    Nihal M; Ahmad N; Wood GS
    Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes.
    Shah ZH; Ahmed SU; Ford JR; Allison SJ; Knight JR; Milner J
    Mol Cell Biol; 2012 Feb; 32(3):704-16. PubMed ID: 22124156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress.
    Hori YS; Kuno A; Hosoda R; Horio Y
    PLoS One; 2013; 8(9):e73875. PubMed ID: 24040102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How does SIRT1 affect metabolism, senescence and cancer?
    Brooks CL; Gu W
    Nat Rev Cancer; 2009 Feb; 9(2):123-8. PubMed ID: 19132007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Sirtuin-1 hyperacetylates p53 and abrogates Sirtuin-1-p53 interaction in Cr(VI)-induced apoptosis in the ovary.
    Sivakumar KK; Stanley JA; Behlen JC; Wuri L; Dutta S; Wu J; Arosh JA; Banu SK
    Reprod Toxicol; 2022 Apr; 109():121-134. PubMed ID: 35307491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRT1 knockdown up-regulates p53 and p21/Cip1 expression in renal adenocarcinoma cells but not in normal renal-derived cells in a deacetylase-independent manner.
    Fujino T; Yokokawa R; Oshima T; Hayakawa M
    J Toxicol Sci; 2018; 43(12):711-715. PubMed ID: 30518708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer.
    Kiga K; Fukuda-Yuzawa Y; Tanabe M; Tsuji S; Sasakawa C; Fukao T
    RNA Biol; 2014; 11(11):1347-54. PubMed ID: 25483038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
    Do MT; Kim HG; Choi JH; Jeong HG
    Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospholipase D2 is a positive regulator of sirtuin 1 and modulates p53-mediated apoptosis via sirtuin 1.
    Lee H; Jung TY; Lim SH; Choi EJ; Lee J; Min DS
    Exp Mol Med; 2021 Sep; 53(9):1287-1297. PubMed ID: 34471223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoring NAD
    Katayoshi T; Nakajo T; Tsuji-Naito K
    J Photochem Photobiol B; 2021 Aug; 221():112238. PubMed ID: 34130091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 and Sirt1: routes of metabolism and genome stability.
    Gonfloni S; Iannizzotto V; Maiani E; Bellusci G; Ciccone S; Diederich M
    Biochem Pharmacol; 2014 Nov; 92(1):149-56. PubMed ID: 25218422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.